Comparison of pregabalin with doxepin in the management of uremic pruritus

Phase 2

• Conditions: ESRD.; End stage kidney disease on dialysis; N 18.5

• Registration Number: IRCT2015060922637N1
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

age between 16-80 years old; undergoing regular hemodialysis or peritoneal dialysis
Exclusion criteria: history of allergy to pregabalin or doxepin; liver failure; pregnancy; history of epilepsy or a single episode of seizure; uncontrolled psychiatric illness; decompensated heart failure; narrow angle glaucoma; hyperthyroidism; history of myocardial infarction in the past three months; heart block; low blood pressure(Systolic blood pressure less than 90 mmHg)

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of pruritus. Timepoint: Before the intervention, and one week, two weeks and four weeks after the intervention. Method of measurement: Visual Analogue Scale.

Secondary Outcome Measures

Name	Time	Method
Severity of pruritus and its impact on the quality of life. Timepoint: Before the intervention, and one week, two weeks and four weeks after the intervention. Method of measurement: 5-D itch scale.;Effect of pruritus on the quality of life. Timepoint: Before the intervention and one week, two weeks and four weeks after the intervention. Method of measurement: Dermatology Life Quality Index (DLQI).;Adverse effects. Timepoint: At the end of the first and fourth weeks of the intervention. Method of measurement: Checklist of adverse effects.